Amide Derivatives Modulating HBV Capsid Assembly
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic hepatitis B virus (HBV) infection are limited by low cure rates, drug resistance, and tolerability issues, with a need for therapeutic agents that can effectively suppress virus production and modulate capsid assembly to improve treatment outcomes.
Innovation Solution
Development of compounds that modulate HBV capsid assembly, disrupting normal capsid assembly and disassembly processes to inhibit viral replication and infectivity, while exhibiting favorable metabolic properties and safety profiles for use in humans.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If interferon alpha or nucleoside analogues are used to treat HBV infection, then viral replication is inhibited, but drug resistance develops and cure rates remain low
Solution Approach 1:
The invention targets a specific segment of the viral life cycle - capsid assembly - rather than relying on broad-spectrum polymerase inhibition. By developing compounds that specifically modulate capsid assembly (CpAMs), the treatment addresses a critical functional step that is essential for viral replication but has not been previously targeted by approved therapies, thereby avoiding cross-resistance with existing nucleoside analogues
Solution Approach 2:
The invention changes the therapeutic parameter from inhibiting viral polymerase activity to modulating capsid assembly dynamics. This parameter shift involves targeting the conformational changes and assembly/disassembly processes of the capsid structure, using compounds that stabilize or destabilize capsid formation depending on the desired therapeutic effect, thereby achieving antiviral activity through a different mechanism that does not induce resistance to existing drugs
2Reliability
If current antiviral agents are used to suppress HBV DNA, then liver disease progression is slowed, but complete suppression of virus production is difficult to achieve
Solution Approach 1:
The invention acts at an early stage in the viral life cycle by targeting capsid assembly before viral DNA replication occurs. By preventing proper capsid formation through assembly modulation, the compound stops the viral life cycle upstream, preventing the generation of infectious virions and reducing the viral reservoir before replication can occur, thereby achieving more complete suppression of virus production
Solution Approach 2:
The capsid assembly modulator acts as an intermediary that disrupts the normal assembly process by binding to core proteins and altering their conformational dynamics. This intermediary action prevents the formation of functional capsids that would otherwise protect and transport viral DNA, effectively blocking viral production without directly interfering with polymerase activity or requiring suppression of integrated viral DNA
3Reliability
If existing HBV treatments are administered, then viral load is reduced, but tolerability issues and side effects limit their impact
Solution Approach 1:
The invention replaces the immunomodulatory mechanism of interferon alpha with a direct molecular mechanism acting on viral proteins. Instead of relying on host immune system activation which causes significant side effects, the compound directly binds to and modulates core protein function, providing a more selective and tolerable treatment that achieves antiviral effects through specific molecular interaction rather than systemic immune activation
Data Source
AI summary
The application relates to amide derivatives of formula (I), processes for their preparation, pharmaceutical compositions, and their uses, more particularly their uses in treating chronic hepatitis B virus (HBV) infection: